.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The OPERA I and OPERA II phase 3 trials compared intravenous ocrelizumab with interferon beta-1a in relapsing multiple sclerosis. The trials showed a significantly lower annualized relapse rate with ocrelizumab along with fewer new or enlarging MRI lesions and fewer disability progression events. The results provided strong evidence that selective B-cell depletion can control inflammatory disease activity more effectively than a conventional interferon platform. Clinically, this helped establish anti-CD20 therapy as a major component of high-efficacy MS treatment. For HCPs, the decision to use ocrelizumab should integrate disease activity, prognostic factors, infection risk, vaccination, immunoglobulin monitoring and patient preference. The study also highlights the importance of distinguishing relapsing inflammatory disease from later progressive phenotypes when selecting treatment. Although ocrelizumab is highly effective, it is not a cure and requires ongoing monitoring. The findings remain central to modern MS practice and align with IANCON's emphasis on evidence-based, disease-modifying treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The OPERA I and OPERA II phase 3 trials compared intravenous ocrelizumab with interferon beta-1a in relapsing multiple sclerosis. The trials showed a significantly lower annualized relapse rate with ocrelizumab along with fewer new or enlarging MRI lesions and fewer disability progression events. The results provided strong evidence that selective B-cell depletion can control inflammatory disease activity more effectively than a conventional interferon platform. Clinically, this helped establish anti-CD20 therapy as a major component of high-efficacy MS treatment. For HCPs, the decision to use ocrelizumab should integrate disease activity, prognostic factors, infection risk, vaccination, immunoglobulin monitoring and patient preference. The study also highlights the importance of distinguishing relapsing inflammatory disease from later progressive phenotypes when selecting treatment. Although ocrelizumab is highly effective, it is not a cure and requires ongoing monitoring. The findings remain central to modern MS practice and align with IANCON's emphasis on evidence-based, disease-modifying treatment.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
